Announcements – Neville Registrars

04 AUGUST 2016

APC Tech Group PLC : Gooee Limited UK launch partnership

RNS Number : 1377G APC Technology Group PLC 04 August 2016 4th August 2016 APC Technology Group PLC ("APC" or the "Group") APC Technology Group announces Gooee Limited UK launch partnership APC Technology Group PLC (AIM: APC), the provider of technologies and services intended to help improve organisational……

03 AUGUST 2016

Rare Earth Minerals : Update on Macarthur Minerals

RNS Number : 0565G Rare Earth Minerals PLC 03 August 2016 Rare Earth Minerals Plc ("Rare Earth Minerals", "REM" or "the Company") Update on Macarthur Minerals Rare Earth Minerals Plc (AIM: REM; OTC: REMMY)) is pleased to report that Macarthur Minerals ("Macarthur") in which REM owns……

RNS Number : 0565G

Rare Earth Minerals PLC

03 August 2016

Rare Earth Minerals Plc

("Rare Earth Minerals", "REM" or "the Company")

Update on Macarthur Minerals

Rare Earth Minerals Plc (AIM: REM; OTC: REMMY)) is pleased to report that Macarthur Minerals ("Macarthur") in which REM owns a 15.5% shareholding, has announced that the majority of its total lithium acreage of 1,489 square kilometres is expected to grant by November / December 2016. The full Macarthur announcement can be found at: http://web.tmxmoney.com/article.php?newsid=8300358548965085&qm_symbol=MMS .

McMahon Mining Title Services Report — Macarthur Minerals Lithium Licences

Macarthur Minerals retains the services of McMahon Mining Title Services ("MMTS") to manage the Company's exploration and mining licences. As detailed in Table 1, MMTS has advised the Company that 13 out of 20 of the Company's Exploration Licence Applications ("Applications") for lithium are expected to grant by November/December 2016.

The grant of exploration licences in Western Australia requires advertisement in accordance with the Mining Act 1978 (WA) ("Mining Act") and subsequent advertisement in accordance with the Native Title Act 1993 (Cth) ("Native Title Act").

All Macarthur Minerals' Applications have been advertised in accordance with the Mining Act and no objections have been maintained. Agreements have been entered into with owners of any overlapping infrastructure leases, where required. An Access Arrangement for Application E46/1115 is currently being finalised.

The majority of Macarthur Minerals' Applications are now progressing through the Native Title Act advertising period, during which, heritage agreements will be entered into with native title parties and provided no objections are raised, are expected to grant in November/December. The remaining Applications will be advertised in the near future.

Until Exploration Licences are granted, the Company will continue prospecting activities to identify exploration targets.

Iron Ore Acreage Update

In addition to Macarthur's lithium acreage, the Company has 15 granted Mining Licences and miscellaneous licences covering 140 square kilometres for its two iron ore projects located North West of Kalgoorlie in Western Australia:

· Ularring Hematite Project consisting of Indicated 54.46 Mt @ 47.2% Fe and Inferred 25.99Mt @ 45.4% Fe3.

· Moonshine Magnetite Project consisting of Inferred Mineral Resource consisting of 1,316 Mt @ 30.1% Fe4.

The Company has received approval to develop an iron ore mine for the Ularring Hematite Project and associated infrastructure under the Environmental Protection Act 1986 and the Environmental and Biodiversity Conservation Act 1999. There are no native title claims affecting the iron ore projects.

Table 1 — Lithium Acreage Expected Acreage Grant Timetable

Tenement	Region	Mining Act Advertised	Native Title Advertised	Expected Grant Date1
E45/4693	Pilbara	No objection	Yes	November
E45/4694	Pilbara	Agreement signed	No	TBA
E45/4702	Pilbara	No objection	Yes	November
E45/4708	Pilbara	Agreement signed	No	TBA
E45/4709	Pilbara	No objection	Yes	October
E45/4710	Pilbara	No objection	Yes	October
E45/4711	Pilbara	Agreement signed	No	TBA
E45/4732	Pilbara	No objection	Yes	November
E45/4735	Pilbara	Agreement signed	No	TBA
E45/4747	Pilbara	Agreement signed	No	TBA
E45/4748	Pilbara	Agreement signed	Yes	January
E45/4749	Pilbara	No objection	Yes	January
E45/4750	Pilbara	No objection	Yes	December
E45/4779	Pilbara	Agreement signed	No	TBA
E46/1114	Pilbara	No objection	Yes	October
E46/1115	Pilbara	Agreement drafted	No	TBA
E46/1133	Pilbara	No objection	Yes	November
E59/2174	Edah	No objection	Yes	October
E74/0587	Ravensthorpe	No objection	Yes	October
E74/0588	Ravensthorpe	No objection	Yes	October

ABOUT MACARTHUR MINERALS LIMITED (TSX VENTURE: MMS)

Macarthur Minerals Limited is an exploration and development company that is focused on identifying and developing high grade lithium and counter cyclical investments that complement Macarthur's capabilities.

For further information, please contact:

Rare Earth Minerals plc +44 (0) 207 440 0647

Andrew Suckling

Kiran Morzaria

WH Ireland Limited (Nomad & Broker) +44 (0) 207 220 1666

James Joyce

James Bavister

Square1 Consulting +44 (0) 207 929 5599

David Bick

Brian Alexander

Qualified Person

Kiran Morzaria B.Eng. (ACSM), MBA, has reviewed and approved the information contained in this announcement. Kiran holds a Bachelor of Engineering (Industrial Geology) from the Camborne School of Mines and an MBA (Finance) from CASS Business School.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCKMGGRNZNGVZM

Close

03 AUGUST 2016

Continued deduction of income tax from interest

The new tax rules apply to dividend payments not interest payments. Therefore tax (currently 20%) continues to be deducted from interest payments from April 2016 onwards where applicable. Banks and Building Societies may have special arrangements to allow interest to be paid gross….

01 AUGUST 2016

Nanoco Group PLC : Nanoco and Merck Sign Agreement

RNS Number : 7626F Nanoco Group PLC 01 August 2016 For immediate release 1 August 2016 NANOCO GROUP PLC ("Nanoco" or the "Company") Nanoco and Merck Sign Agreement on Eco-Friendly Quantum Materials for Displays · Cadmium-free quantum dots enable ultra-bright displays……

RNS Number : 7626F

Nanoco Group PLC

01 August 2016

For immediate release

1 August 2016

NANOCO GROUP PLC

("Nanoco" or the "Company")

Nanoco and Merck Sign Agreement on

Eco-Friendly Quantum Materials for Displays

· Cadmium-free quantum dots enable ultra-bright displays with a substantially extended colour range

· Nanoco enters into a non-exclusive licence agreement with Merck, which will market Nanoco's material to its broad customer base in the display industry

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, and Merck, a leading science and technology company, today announced the signing of a worldwide material supply and licensing agreement. The licence allows Merck to immediately start marketing Nanoco's cadmium-free quantum dots and to ultimately establish its own production facility to meet growing market demand.

"The agreement is in line with Merck's strategy to sustainably secure its position as the global market and technology leader in display materials. With cadmium-free quantum dots a remarkable increase in the colour range and a significant reduction in power consumption can be achieved. These cadmium-free quantum dots are eco-friendly and also complement our product portfolio for the display industry," said Walter Galinat, member of the Merck Executive Board and CEO of Performance Materials. "The licence agreement with Nanoco will strengthen our position in quantum materials research, for which we laid the foundations by acquiring Qlight Nanotech of Israel last year."

The financial details of the agreement are not being disclosed, but Nanoco will receive a licence fee and royalties on Merck's sales of the Nanoco cadmium-free quantum dots Merck manufactures. In line with Nanoco's commercialisation strategy in the display market, this agreement is non-exclusive. Merck will begin marketing Nanoco's technology in the near term by selling cadmium-free quantum dots manufactured at Nanoco's expanded production plant in Runcorn, UK. The licence allows Merck to establish its own production facility for cadmium-free quantum dots in line with global market demand at a later point in time. Michael Edelman, Nanoco's Chief Executive Officer, added: "This agreement with Merck is another major endorsement of the world-class quality of our cadmium free quantum dot technology. We are convinced that Merck can leverage its position in the display industry with these innovative materials."

Advantages of quantum materials

Quantum materials offer a substantial additional benefit when they are used as color converters in the light source of liquid crystal displays. In conventional displays, the colors blue, green, and red are filtered out of the original white light of the LED light source. A great deal of light is lost in this process. Because a blue LED in combination with red and green quantum materials only generates the blue, green and red light that is perfectly transmitted through the filters, there is much less absorption. This increases the display's brightness, reduces electricity consumption and leads to much purer and potentially stronger colors.

This announcement contains inside information.

For further information, please contact:

Nanoco	Tel: +44 (0) 161 603 7900
Michael Edelman, Chief Executive Officer
David Blain, Chief Financial Officer Caroline Watson, Investor Relations Manager cwatson@nanocotechnologies.com	Tel: + 44 (0) 7799 897357

Canaccord Genuity – Joint Broker	Tel: +44 (0) 20 7523 8000
Simon Bridges Cameron Duncan
Richard Andrews

Liberum – Joint Broker	Tel: +44 (0) 20 3100 2000
Neil Patel
Richard Bootle Steven Tredget

Buchanan	Tel: +44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Stephanie Watson

Notes for editors:

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LC displays, lighting, solar cells and bio-imaging. In the display market, Nanoco has non-exclusive manufacturing and marketing licensing agreements with The Dow Chemical Company and Taiwan's Wah Hong Industrial Corporation. Nanoco also has a strategy of direct sales in display and in its other target markets, including lighting.

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Greater China. Its technology is protected worldwide by a large and growing patent estate.

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGRKMGFNGMFGVZZ

Close

26 JULY 2016

Concepta PLC : Admission to AIM

RNS Number : 1752F Concepta PLC 26 July 2016 26 July 2016 Concepta plc ("Concepta" or the "Company") Admission to AIM Concepta plc (AIM:CPT), the pioneering UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market with a……

RNS Number : 1752F

Concepta PLC

26 July 2016

Concepta plc ("Concepta" or the "Company")

Admission to AIM

Concepta plc (AIM:CPT), the pioneering UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility, announces that Admission of its Enlarged Share Capital to trading on AIM has now commenced under the symbol "CPT". SPARK Advisory Partners is acting as Nominated Adviser and Financial Adviser to the Company with Beaufort Capital as Broker.

· Innovative player in the Mobile Health and Connected Health Sector

· Developed pioneering product 'MyLotus' for home self-testing that helps women with unexplained infertility to conceive

· MyLotus – only known consumer product to allow both quantitative and qualitative measurement of a woman's personal hCG and LH hormone levels in urine samples to help increase conception rates

· Defined route to market:

o Regulatory approvals in place for launch in China – first order from distributor with payment in advance expected after AIM admission

o CE-Marking for UK and Europe to follow in 2017

· Significant market opportunity – Chinese and EU infertility market worth c.£600m per annum

· Management has proven track record in the women's health diagnostics industry

· New Product Development growth opportunities – proprietary platform lends itself to wider family home-health monitoring to improve individual health parameters including chronic stress, inflammation, urinary tract and healthy pregnancy progression et al.

Concepta's AIM Admission follows a reverse takeover from Frontier Resources International plc ("Frontier"), the details of which can be found in the announcement made by Frontier on 25 July 2016 'Result Of General Meetings And Open Offer'.

Erik Henau, Chief Executive Officer of Concepta plc said: "We are delighted to be joining AIM at this transformational juncture of our development and believe our listing will significantly enhance our profile and visibility with future customers and partners, as we look to launch our pioneering 'My Lotus' product, targeted at helping women with unexplained infertility to conceive, across key international growth markets.

"Unexplained infertility refers to women who have been unable to conceive after six months of trying for a baby. The issue is universal and largely unaffected by demographics, and accounts for 0.36% of the total population in any given market. Many women within this group often have to wait months or even years before they are eligible for medical intervention which can lead to a long and worrying wait for women and families, not knowing whether or not anything is wrong. As such, the market opportunity for a 'best in class' product specifically aiming to help women with unexplained infertility to conceive is huge, representing a highly motivated yet neglected group.

"We are expecting a highly active start to our life on AIM, with the roll out of My Lotus in China set to commence in Q3 2016 and thereafter in the UK and Europe in 2017. In addition, our proprietary platform lends itself to wider family home-health monitoring, and we believe there are exciting growth opportunities for Concepta in the future within the growing global connected healthcare sector set to be worth $61bn by 2020 (PwC).

"Finally, the board joins me in welcoming our new and existing shareholders to our register and we now look forward to implementing our defined growth strategy focused on delivering commercial success and becoming the global market leaders for over-the counter products for women with fertility issues."

**ENDS**

Enquiries:

The Company

Adam Reynolds, Chairman

Tel: +44 (0) 7785 908158

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin/Mark Brady

Tel: +44 (0)20 368 3550

Beaufort Securities Limited (Broker)

Jon Belliss

Tel: +44 (0)20 7382 8300

Yellow Jersey PR Limited (Financial PR)

Felicity Winkles/ Joe Burgess/ Josh Cole

Tel: +44 (0) 7748 843 871

About Concepta Plc:

Concepta plc is a pioneering UK healthcare company that has developed a proprietary platform and products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility*.

Founded in 2013, Concepta has developed a revolutionary flagship product 'MyLotus' for home self-testing that helps women with unexplained infertility to conceive.

MyLotus is the only consumer product which allows both quantitative and qualitative measurements of measurement of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems. Competitor products currently only allow qualitative measurement and are based on the 'average woman'.

Concepta has a defined route to market for its new 'My Lotus' product with Regulatory approvals for launch in China in place for 2016 and CE-Marking for UK and Europe to follow in 2017 where the revenue potential of the Chinese and EU infertility market is worth c.£600m per annum for the company.

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPGURUMUPQGQA

Close

25 JULY 2016

Genedrive PLC : Re change of name TIDM and website address

RNS Number : 0632F Genedrive PLC 25 July 2016 RNS For release: 25 July 2016 Genedrive plc ("Genedrive" or the "Company") Re change of name, TIDM and website address Genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that further to obtaining……

19 JULY 2016

Pennant Int. Group : Record Order Book drives expansion of premises

RNS Number : 5582E Pennant International Group PLC 19 July 2016 19 July 2016 Pennant International Group plc (AIM: PEN) Record Order Book Drives Expansion of Pennant's Business Premises Pennant International Group plc, ("Pennant" or "the Group"), the AIM quoted supplier of integrated logistic support solutions, products and……

18 JULY 2016

Nasstar PLC : Rebrand and Website Launch

RNS Number : 3785E Nasstar PLC 18 July 2016 Nasstar plc ("Nasstar", "Company" or "Group") Nasstar rebrand and website Launch 18th July 2016 Nasstar (stock code: NASA), a provider of hosted managed and cloud computing services, is pleased to announce the delivery of a key strategic aim for……

18 JULY 2016

Crimson Tide PLC : Crimson Tide selected by large UK retailer

RNS Number : 3920E Crimson Tide PLC 18 July 2016 Crimson Tide PLC ("Crimson Tide" or the 'Company') Crimson Tide selected by large UK retailer Crimson Tide (TIDE), the AIM-quoted provider of mpro5 – Smart Mobility as a Service, has won a contract with a large……

RNS Number : 3920E

Crimson Tide PLC

18 July 2016

Crimson Tide PLC

("Crimson Tide" or the 'Company')

Crimson Tide selected by large UK retailer

Crimson Tide (TIDE), the AIM-quoted provider of mpro5 – Smart Mobility as a Service, has won a contract with a large UK retailer whereby mpro5 will be used to monitor store safety, cleanliness and security. The initial contract value for a pilot period is approximately £200,000. Subject to a successful pilot period, the retailer will deploy mpro5 for a 48-month term with a considerably higher value.

The roll-out involves implementing the mobility platform to enable the scheduling of regular cleaning, reactive cleaning and incident capture as well as providing dynamic audits and bespoke management dashboards. Jobs are scheduled via the mpro5 website, and are then pushed to a mobile device. Remote users monitor business workflows and capture pertinent information which is then automatically synchronised with the cloud to the central repository. Real time audit dashboards and reports are securely shared to relevant management.

mpro5 provides barcode scanning and cloud-based synchronisation services via Microsoft Azure, renowned for its reliability, scalability and security. This enables real-time information upload, quick verifications and multi-way data request transmittals.

This customer stands to benefit from improvements in reporting and visibility, quality auditing, health and safety, financial savings, consumer satisfaction and overall efficiency and productivity. mpro5 provides additional protection against any spurious 'slip-and-trip' claims in large, multi-site retail environments.

Barrie Whipp, Executive Chairman of Crimson Tide, said: "Our team has worked diligently in providing a solid business case to our client, which has resulted in this success. I am delighted we are able to assist this household-name customer in transforming its business and ultimately providing true ROI using mpro5."

‐ ends ‐

For further information:

Crimson Tide plc

Barrie Whipp 01892 542 444

Steve Goodwin

WH Ireland

James Joyce /James Bavister 020 7220 1666

Allerton Communications

Peter Curtain 020 3137 2500

peter.curtain@allertoncomms.co.uk

Notes to editors

Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 – Smart Mobility as a Service (SMaaS). mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world-class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

mpro5 is a platform-agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

mpro5 not only helps people improve their day-to-day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to listen, share and find the best solution for all mobility needs.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCGGUPCMUPQPUM

Close

18 JULY 2016

Transense Technlgy : Licence Agreement with GE

RNS Number : 3908E Transense Technologies PLC 18 July 2016 18 July 2016 Transense Technologies Plc ("Transense" or "the Company") Licence Agreement with GE Transense Technologies Plc (AIM: TRT), the provider of sensor systems for the transportation and industrial markets, is pleased to announce that it has……

APC Technology Group PLC	01634 290 588
Leonard Seelig, Chairman Richard Hodgson, Chief Executive	www.apc-plc.co.uk
Stockdale Securities Limited (Nominated Advisor and Broker)	020 7601 6100
Mark Brown / Antonio Bossi / Edward Thomas
Redleaf Communications (Financial PR)	020 7382 4730
Rebecca Sanders-Hewett / David Ison / Susie Hudson

Enquiries:

Pennant International Group plc	www.pennantplc.co.uk
Phil Walker, CFO	+44 (0) 1452 714 914
Chris Snook, CEO	+44 (0) 1452 714 914

WH Ireland Limited	www.wh-ireland.co.uk
Mike Coe / Ed Allsopp	+44 (0) 117 945 3470

Walbrook PR	www.walbrookpr.com
Paul Vann / Tom Cooper	+44 (0) 117 985 8989 Mob: 07768 807631